Correspondence 0001193125-22-309213 from HTG MOLECULAR DIAGNOSTICS, INC (HTGMQ) (CIK 0001169987)
HTG MOLECULAR DIAGNOSTICS, INC (HTGMQ) (CIK 0001169987)
Date: Dec. 20, 2022 · CIK: 0001169987 · Accession: 0001193125-22-309213
AI Filing Summary & Sentiment
File numbers found in text: 333-268681
Letter
Steven M. Przesmicki
+1 858 550 6070
przes@cooley.com
December 20, 2022
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Benjamin Richie and Abby Adams
Re: HTG Molecular Diagnostics, Inc.
Registration Statement on Form S-1
Filed December 6, 2022
File No. 333-268681
Ladies and Gentlemen:
On behalf of HTG Molecular Diagnostics, Inc. (the “Company”), we are responding to the comment (the “Comment”) of the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) contained in its letter, dated December 16, 2022 (the “Comment Letter”), relating to the above referenced Registration Statement on Form S-1 (the “Registration Statement”).
In response to the Comment set forth in the Comment Letter, the Company has revised the Registration Statement and will be filing via EDGAR an Amendment No. 1 to the Registration Statement on Form S-1 (the “Amended Registration Statement”).
Set forth below is the Company’s response to the Comment.
Registration Statement on Form S-1 filed December 6, 2022
Plan of Distribution, page 20
1. We note that you may enter into a securities purchase agreement directly with certain institutional investors but investors that do not enter into a such an agreement shall rely solely on the prospectus in connection with the purchase. Please provide additional disclosure regarding this disparate treatment and how you intend to address details of transactions outside of a securities purchase agreement, such as the number of securities to be purchased. Alternatively, revise to clarify that all investors will enter into the same agreement.
Response: In response to the Staff’s comment, the Company has revised its disclosure in the Plan of Distribution section to provide that all investors will enter into a securities purchase agreement with the Company in the form attached as an exhibit to the Registration Statement.
In addition, pursuant to an oral conversation with the Staff, we are providing the Staff with the below proposed disclosure to be included in the “Plan of Distribution” section of the Amended Registration Statement, relating to a potential warrant modification that may be effected concurrently with the offering.
Potential Modification of Certain Outstanding Warrants
In connection with this offering, we may amend the terms of outstanding warrants to purchase up to an aggregate of 540,830 shares of our common stock having an exercise price of $24.744 per share, originally issued on March 21, 2022, to reduce the exercise price of such outstanding warrants to equal the exercise price of the warrants issued in this offering, and to extend the expiration dates of such outstanding warrants to coincide with the expiration date of the Series A-1 warrants, subject to the holder of those warrants purchasing securities in this offering. Fifty percent of the outstanding warrants issued on March 21, 2022 are currently set to expire March 21, 2024 and the remaining 50% of such warrants are currently set to expire on September 21, 2027.
Similar disclosure, along with a cross-reference to the above disclosure in the “Plan of Distribution” section, would be included in the “Summary” and “Dilution” sections of the Amended Registration Statement.
* * *
Cooley LLP 10265 Science Center Drive San Diego, CA 92121-1117
t: (858) 550-6000 f: (858) 550-6420 cooley.com
U.S. Securities and Exchange Commission
December 20, 2022
Page Two
The Company respectfully requests the Staff’s assistance in completing the review of the matters set forth in this letter as soon as possible. Please advise us if we can provide any further information or assistance to facilitate your review. Please contact me at (858) 550-6070 or Asa M. Henin of Cooley LLP at (858) 550-6104 with any questions or further comments regarding our response to the Comment.
Sincerely,
/s/ Steven M. Przesmicki
Show Raw Text
CORRESP 1 filename1.htm CORRESP Steven M. Przesmicki +1 858 550 6070 przes@cooley.com December 20, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Benjamin Richie and Abby Adams Re: HTG Molecular Diagnostics, Inc. Registration Statement on Form S-1 Filed December 6, 2022 File No. 333-268681 Ladies and Gentlemen: On behalf of HTG Molecular Diagnostics, Inc. (the “Company”), we are responding to the comment (the “Comment”) of the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) contained in its letter, dated December 16, 2022 (the “Comment Letter”), relating to the above referenced Registration Statement on Form S-1 (the “Registration Statement”). In response to the Comment set forth in the Comment Letter, the Company has revised the Registration Statement and will be filing via EDGAR an Amendment No. 1 to the Registration Statement on Form S-1 (the “Amended Registration Statement”). Set forth below is the Company’s response to the Comment. Registration Statement on Form S-1 filed December 6, 2022 Plan of Distribution, page 20 1. We note that you may enter into a securities purchase agreement directly with certain institutional investors but investors that do not enter into a such an agreement shall rely solely on the prospectus in connection with the purchase. Please provide additional disclosure regarding this disparate treatment and how you intend to address details of transactions outside of a securities purchase agreement, such as the number of securities to be purchased. Alternatively, revise to clarify that all investors will enter into the same agreement. Response: In response to the Staff’s comment, the Company has revised its disclosure in the Plan of Distribution section to provide that all investors will enter into a securities purchase agreement with the Company in the form attached as an exhibit to the Registration Statement. In addition, pursuant to an oral conversation with the Staff, we are providing the Staff with the below proposed disclosure to be included in the “Plan of Distribution” section of the Amended Registration Statement, relating to a potential warrant modification that may be effected concurrently with the offering. Potential Modification of Certain Outstanding Warrants In connection with this offering, we may amend the terms of outstanding warrants to purchase up to an aggregate of 540,830 shares of our common stock having an exercise price of $24.744 per share, originally issued on March 21, 2022, to reduce the exercise price of such outstanding warrants to equal the exercise price of the warrants issued in this offering, and to extend the expiration dates of such outstanding warrants to coincide with the expiration date of the Series A-1 warrants, subject to the holder of those warrants purchasing securities in this offering. Fifty percent of the outstanding warrants issued on March 21, 2022 are currently set to expire March 21, 2024 and the remaining 50% of such warrants are currently set to expire on September 21, 2027. Similar disclosure, along with a cross-reference to the above disclosure in the “Plan of Distribution” section, would be included in the “Summary” and “Dilution” sections of the Amended Registration Statement. * * * Cooley LLP 10265 Science Center Drive San Diego, CA 92121-1117 t: (858) 550-6000 f: (858) 550-6420 cooley.com U.S. Securities and Exchange Commission December 20, 2022 Page Two The Company respectfully requests the Staff’s assistance in completing the review of the matters set forth in this letter as soon as possible. Please advise us if we can provide any further information or assistance to facilitate your review. Please contact me at (858) 550-6070 or Asa M. Henin of Cooley LLP at (858) 550-6104 with any questions or further comments regarding our response to the Comment. Sincerely, /s/ Steven M. Przesmicki Steven M. Przesmicki Cooley LLP cc: Shaun D. McMeans, HTG Molecular Diagnostics, Inc. Asa M. Henin, Cooley LLP Robert F. Charron, Ellenoff Grossman & Schole LLP Cooley LLP 10265 Science Center Drive San Diego, CA 92121-1117 t: (858) 550-6000 f: (858) 550-6420 cooley.com